Ken M Kunisaki1,2, Davide De Francesco3, Caroline A Sabin3, Alan Winston4, Patrick W G Mallon5, Jane Anderson6, Emmanouil Bagkeris3, Marta Boffito7, Nicki Doyle4, Lewis Haddow3,8, Frank A Post9, Memory Sachikonye10, Jaime Vera11, Wajahat Khalil1,2, Susan Redline12,13,14. 1. Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, USA. 2. University of Minnesota, Minneapolis, Minnesota, USA. 3. University College London, London, United Kingdom. 4. Imperial College London, London, United Kingdom. 5. University College Dublin, Dublin, Ireland. 6. Homerton University Hospital, London, United Kingdom. 7. Chelsea and Westminster Healthcare NHS Foundation Trust, London, United Kingdom. 8. Kingston Hospital NHS Foundation Trust, London, United Kingdom. 9. King's College Hospital NHS Foundation Trust, London, United Kingdom. 10. UK Community Advisory Board (UK-CAB), London, United Kingdom. 11. Brighton and Sussex Medical School, Brighton, United Kingdom. 12. Brigham and Women's Hospital, Boston, Massachusetts, USA. 13. Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 14. Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Self-reported sleep quality is poor in persons with human immunodeficiency virus (PWH), but prior studies commonly used nonspecific questionnaires, investigated only single sleep disorders, or lacked human immunodeficiency virus (HIV)-negative controls. We addressed these limitations in the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Sleep Substudy by assessing PWH and HIV-negative controls for insomnia, restless legs syndrome (RLS), and sleep apnea (SA). METHODS: Previously enrolled POPPY participants coenrolled in this substudy without regard to sleep symptoms. Participants completed validated sleep assessments including the Insomnia Severity Index questionnaire, International Restless Legs Syndrome Study Group questionnaire, and in-home, wrist-worn overnight oximetry. They also completed health-related quality of life questionnaires including 36-item Short Form (SF-36) and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep questionnaires. RESULTS: We enrolled 357 PWH (246 >50 years of age; 111 between 18 and 50 years) and 126 HIV-negative controls >50 years of age. Among PWH, criteria were met by 21% for insomnia, 13% for RLS, and 6% for SA. Compared with HIV-negative controls, PWH had a higher risk of insomnia (adjusted odds ratio, 5.3; 95% confidence interval, 2.2-12.9) but not RLS or SA. Compared with PWH without insomnia, those with insomnia reported significantly worse scores on all SF-36 and PROMIS components; fewer than 30% reported previous diagnosis or treatment for insomnia. CONCLUSIONS: Insomnia was more common in PWH, associated with worse health-related quality of life, and frequently undiagnosed. Further research should focus on the pathogenesis of insomnia in PWH and the development of effective screening and intervention strategies for this unique population. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.
BACKGROUND: Self-reported sleep quality is poor in persons with human immunodeficiency virus (PWH), but prior studies commonly used nonspecific questionnaires, investigated only single sleep disorders, or lacked human immunodeficiency virus (HIV)-negative controls. We addressed these limitations in the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Sleep Substudy by assessing PWH and HIV-negative controls for insomnia, restless legs syndrome (RLS), and sleep apnea (SA). METHODS: Previously enrolled POPPY participants coenrolled in this substudy without regard to sleep symptoms. Participants completed validated sleep assessments including the Insomnia Severity Index questionnaire, International Restless Legs Syndrome Study Group questionnaire, and in-home, wrist-worn overnight oximetry. They also completed health-related quality of life questionnaires including 36-item Short Form (SF-36) and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep questionnaires. RESULTS: We enrolled 357 PWH (246 >50 years of age; 111 between 18 and 50 years) and 126 HIV-negative controls >50 years of age. Among PWH, criteria were met by 21% for insomnia, 13% for RLS, and 6% for SA. Compared with HIV-negative controls, PWH had a higher risk of insomnia (adjusted odds ratio, 5.3; 95% confidence interval, 2.2-12.9) but not RLS or SA. Compared with PWH without insomnia, those with insomnia reported significantly worse scores on all SF-36 and PROMIS components; fewer than 30% reported previous diagnosis or treatment for insomnia. CONCLUSIONS: Insomnia was more common in PWH, associated with worse health-related quality of life, and frequently undiagnosed. Further research should focus on the pathogenesis of insomnia in PWH and the development of effective screening and intervention strategies for this unique population. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.
Authors: Jacqueline Neuhaus; David R Jacobs; Jason V Baker; Alexandra Calmy; Daniel Duprez; Alberto La Rosa; Lewis H Kuller; Sarah L Pett; Matti Ristola; Michael J Ross; Michael G Shlipak; Russell Tracy; James D Neaton Journal: J Infect Dis Date: 2010-06-15 Impact factor: 5.226
Authors: Lan Yu; Daniel J Buysse; Anne Germain; Douglas E Moul; Angela Stover; Nathan E Dodds; Kelly L Johnston; Paul A Pilkonis Journal: Behav Sleep Med Date: 2011-12-28 Impact factor: 2.964
Authors: Charlene E Gamaldo; Alyssa Gamaldo; Jason Creighton; Rachel E Salas; Ola A Selnes; Paula M David; Gilbert Mbeo; Benjamin S Parker; Amanda Brown; Justin C McArthur; Michael T Smith Journal: J Acquir Immune Defic Syndr Date: 2013-08-15 Impact factor: 3.731
Authors: Emmanouil Bagkeris; Laura Burgess; Patrick W Mallon; Frank A Post; Marta Boffito; Memory Sachikonye; Jane Anderson; David Asboe; Lucy Garvey; Jaime Vera; Ian Williams; Margaret Johnson; Daphne Babalis; Davide De Francesco; Alan Winston; Caroline A Sabin Journal: Int J Epidemiol Date: 2018-10-01 Impact factor: 7.196
Authors: Caroline A Sabin; Richard Harding; Nicki Doyle; Susan Redline; Davide de Francesco; Patrick W G Mallon; Frank A Post; Marta Boffito; Memory Sachikonye; Adam Geressu; Alan Winston; Ken M Kunisaki Journal: J Acquir Immune Defic Syndr Date: 2020-09-01 Impact factor: 3.771
Authors: Kelly Safreed-Harmon; Maria J Fuster-RuizdeApodaca; Marta Pastor de la Cal; Jeffrey V Lazarus Journal: Health Qual Life Outcomes Date: 2022-05-25 Impact factor: 3.077
Authors: Davide De Francesco; Caroline A Sabin; Alan Winston; Patrick W G Mallon; Jane Anderson; Marta Boffito; Nicki D Doyle; Lewis Haddow; Frank A Post; Jaime H Vera; Memory Sachikonye; Susan Redline; Ken M Kunisaki Journal: AIDS Date: 2021-06-01 Impact factor: 4.632
Authors: Davide De Francesco; Jonathan Underwood; Jane Anderson; Marta Boffito; Frank A Post; Memory Sachikonye; Patrick W G Mallon; Lewis Haddow; Jaime H Vera; Ken M Kunisaki; Caroline A Sabin; Alan Winston Journal: AIDS Care Date: 2020-12-28
Authors: Leonard Ngarka; Joseph Nelson Siewe Fodjo; Esraa Aly; Willias Masocha; Alfred K Njamnshi Journal: Front Immunol Date: 2022-01-13 Impact factor: 8.786
Authors: Douglas M Wallace; Maria L Alcaide; William K Wohlgemuth; Deborah L Jones Weiss; Claudia Uribe Starita; Sanjay R Patel; Valentina Stosor; Andrew Levine; Carling Skvarca; Dustin M Long; Anna Rubtsova; Adaora A Adimora; Stephen J Gange; Amanda B Spence; Kathryn Anastos; Bradley E Aouizerat; Yaacov Anziska; Naresh M Punjabi Journal: PLoS One Date: 2021-10-01 Impact factor: 3.752
Authors: H Okhai; C Sabin; K Haag; L Sherr; R Dhairyawan; J Shephard; G Richard; F Burns; F Post; R Jones; Y Gilleece; S Tariq Journal: AIDS Behav Date: 2022-05-23
Authors: Maria José Fuster-RuizdeApodaca; Kelly Safreed-Harmon; Marta Pastor de la Cal; Ana Laguia; Denise Naniche; Jeffrey V Lazarus Journal: Front Psychol Date: 2021-06-09